RT @SABOURETCardio: Thanks to @matiasrg . https://t.co/RW0PMu4n4s
Thanks to @matiasrg . https://t.co/RW0PMu4n4s
Just a reminder: Is there a place for a more expensive and twice-a-day drug after STEMI pts treated with lytics instead of clopidogrel? No 😊👇🏻 https://t.co/uUkQgHaeum
@AzuSuave https://t.co/HiqnThZvdg Quizás con una n mayor probablemente saldría con una P significativa. Aunque esto fue un estudio de no-inferioridad. No sé si en las próximas guías permitirán el Tica como AAG para FBN. A mi resulta interesante sobre todo
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
RT @alexariasmx20: el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrel…
el clopidogrel es el antiplaquetario a usar, carga de 300 mg en < 75 años, en pacientes de 75 años o > no carga Ticagrelor se puede usar después de fibrinolisis generalmente después de 24hs - Treat trial @paomorejon @DanielSierraLM @MediCasos @medico
RT @ISeropianMD: @MediCasos Muy buena iniciativa! 👏 como veo que las respuestas se fueron “un poco por las ramas”… vous dejar esto por acá…
RT @ISeropianMD: @MediCasos Muy buena iniciativa! 👏 como veo que las respuestas se fueron “un poco por las ramas”… vous dejar esto por acá…
@MediCasos Muy buena iniciativa! 👏 como veo que las respuestas se fueron “un poco por las ramas”… vous dejar esto por acá https://t.co/qsbbAdsaPf
Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. - PubMed - NCBI https://t.co/G5oomjGjLv https://t.co/KYskAtNhAq
Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis https://t.co/cZSxWnTmc6
@swatirao24 @UofUMedicine grad! #proud to claim as ours.
Interesting case at our weekly #CCUconference by @swatirao24. Rare use of fibrinolytics for STEMI transfer that would’ve been > 120 min time frame. Question of ticagrelor vs clopidogrel for these patients led to discussion of recent TREAT trial https://
New2Trip: Ticagrelor Versus Clopidogrel in Patients w/ STEMI Treated w/ Fibrinolysis: TREAT Trial https://t.co/DQ5UZPqvtK
New2Trip: Ticagrelor Versus Clopidogrel in Patients w/ STEMI Treated w/ Fibrinolysis: TREAT Trial https://t.co/DQ5UZPqvtK
New2Trip: Ticagrelor Versus Clopidogrel in Patients w/ STEMI Treated w/ Fibrinolysis: TREAT Trial https://t.co/DQ5UZPqvtK
RT @Medtorek: #pacientes < 75 años con SCACEST, #ticagrelor tras tto con fibrinolíticos no redujo significativamente frecuencia eventos CVs…
RT @Medtorek: #pacientes < 75 años con SCACEST, #ticagrelor tras tto con fibrinolíticos no redujo significativamente frecuencia eventos CVs…
RT @Medtorek: #pacientes < 75 años con SCACEST, #ticagrelor tras tto con fibrinolíticos no redujo significativamente frecuencia eventos CVs…
RT @Medtorek: #pacientes < 75 años con SCACEST, #ticagrelor tras tto con fibrinolíticos no redujo significativamente frecuencia eventos CVs…
RT @Medtorek: #pacientes < 75 años con SCACEST, #ticagrelor tras tto con fibrinolíticos no redujo significativamente frecuencia eventos CVs…
RT @Medtorek: #pacientes < 75 años con SCACEST, #ticagrelor tras tto con fibrinolíticos no redujo significativamente frecuencia eventos CVs…
#pacientes < 75 años con SCACEST, #ticagrelor tras tto con fibrinolíticos no redujo significativamente frecuencia eventos CVs en comparación con #clopidogrel @vic_pallares @VicenteLozadaB @secardiologia @chemachir @fcbzafra https://t.co/ss5ZXb6
RT @FarmaMadridAP: (JACC) Entre los pacientes < 75 años con SCACEST, el uso de ticagrelor tras el tto con fibrinolíticos no redujo signific…
RT @FarmaMadridAP: (JACC) Entre los pacientes < 75 años con SCACEST, el uso de ticagrelor tras el tto con fibrinolíticos no redujo signific…
RT @FarmaMadridAP: (JACC) Entre los pacientes < 75 años con SCACEST, el uso de ticagrelor tras el tto con fibrinolíticos no redujo signific…
RT @FarmaMadridAP: (JACC) Entre los pacientes < 75 años con SCACEST, el uso de ticagrelor tras el tto con fibrinolíticos no redujo signific…
RT @FarmaMadridAP: (JACC) Entre los pacientes < 75 años con SCACEST, el uso de ticagrelor tras el tto con fibrinolíticos no redujo signific…
RT @FarmaMadridAP: (JACC) Entre los pacientes < 75 años con SCACEST, el uso de ticagrelor tras el tto con fibrinolíticos no redujo signific…
(JACC) Entre los pacientes < 75 años con SCACEST, el uso de ticagrelor tras el tto con fibrinolíticos no redujo significativamente la frecuencia de eventos CVs en comparación con clopidogrel https://t.co/P2v9S85L2X
RT @rincondesisifo: (JACC) Ticagrelor vs clopidogrel en pac con SCACEST sometidos a fibrinolisis https://t.co/hQWYQ1zVDe ECA #TREAT https:/…
Ticagrelor não superior a clopidogrel em doentes com EAM com supra ST submetido a fibrinólise. https://t.co/wLS7UUKFOZ #experimental #evidentiamedica
RT @rincondesisifo: (JACC) Ticagrelor vs clopidogrel en pac con SCACEST sometidos a fibrinolisis https://t.co/hQWYQ1zVDe ECA #TREAT https:/…
(JACC) Ticagrelor vs clopidogrel en pac con SCACEST sometidos a fibrinolisis https://t.co/hQWYQ1zVDe ECA #TREAT https://t.co/6EMlWs0T1h
Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. - PubMed - NCBI https://t.co/bvY1mFGiQm
Results from the #TREAT trial: patients receiving #Ticagrelor trial s/p lytics did not have a lower risk of #MACE compared to #Clopidogrel. Good to think about, given the patient transfers we get from #rural #underserved areas. #STEMI @drdargaray #cardiotw
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @paomorejon: Estudio con gran aporte argentino, análisis estadístico a cargo del Grupo GEDIC, liderado por los Drs. Tajer y Doval. https…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
Estudio con gran aporte argentino, análisis estadístico a cargo del Grupo GEDIC, liderado por los Drs. Tajer y Doval.
RT @drdargaray: TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with cl…
TREAT Trial: ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of MACE when compared with clopidogrel. @JACCJournals - How frequently do you see patients w/STEMI going lysis? We still se a lot! #Mexico #CardioTwitter https
Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial https://t.co/8MY5tz9an0
TREAT: Ticagrelor vs. clopidogrel in patients who were treated with a fibrinolytic for STEMI - no difference in secondary composite endpoint of CV death, MI or stroke between groups at 12 mo. https://t.co/XYMvfwdUqJ @JACCJournals https://t.co/oTyPmjBdL2
RT @ATRIUMRx: TREAT: Ticagrelor vs. clopidogrel in patients who were treated with a fibrinolytic for STEMI - no difference in secondary com…
TREAT: Ticagrelor vs. clopidogrel in patients who were treated with a fibrinolytic for STEMI - no difference in secondary composite endpoint of CV death, MI or stroke between groups at 12 mo. https://t.co/XYMvfwvvih @JACCJournals https://t.co/NBWa0kuRj4
RT @JACCJournals: Administration of ticagrelor after fibrinolytic therapy may not reduce the frequency of major adverse cardiac events comp…
RT @JACCJournals: Administration of ticagrelor after fibrinolytic therapy may not reduce the frequency of major adverse cardiac events comp…
RT @JACCJournals: Administration of ticagrelor after fibrinolytic therapy may not reduce the frequency of major adverse cardiac events comp…
Administration of ticagrelor after fibrinolytic therapy may not reduce the frequency of major adverse cardiac events compared with clopidogrel. https://t.co/9dAbaGwAtE #JACC https://t.co/QICHZBDGAe
RT @novitskiynic: TREAT trial🚑: most pts received #clopidogrel prior to randomization⤵️ It’s possible to safely transfer #STEMI pts aged <…
RT @novitskiynic: TREAT trial🚑: most pts received #clopidogrel prior to randomization⤵️ It’s possible to safely transfer #STEMI pts aged <…
RT @novitskiynic: TREAT trial🚑: most pts received #clopidogrel prior to randomization⤵️ It’s possible to safely transfer #STEMI pts aged <…
RT @novitskiynic: TREAT trial🚑: most pts received #clopidogrel prior to randomization⤵️ It’s possible to safely transfer #STEMI pts aged <…
TREAT trial🚑: most pts received #clopidogrel prior to randomization⤵️ It’s possible to safely transfer #STEMI pts aged <75 years, who had originally received clopidogrel, to #ticagrelor therapy for the first 24 hours after thrombolysis @JACCJournals h
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
RT @drjarayg: Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @…
Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial https://t.co/gx8YlJ7pG5 @ernestocardio @gonzaeperez @cardioprevanz @recetario1 @jstragazue @DrPontecarlosi @mancebin @SalazarMJA @sandrapaulinarg @mencardio
Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibr... https://t.co/xEoMCl6QPC
75歳未満の線溶療法を受けたST上昇型急性心筋梗塞患者において、チガグレロルはクロピドグレルと比較して心血管死亡や心筋梗塞、脳卒中の複合アウトカムを有意に減少させなかった。 https://t.co/DOtaCpwCJC
Ticagrelor versus Clopidogrel in Patients with STEMI Treated with Fibrinolytic Therapy: TREAT Trial. https://t.co/mw0ZbvQObN
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
RT @vass_vassiliou: For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not s…
For the places offering thrombolysis (and not PPCI) long-term ticagrelor did not perform better than clopidigrel. Not surprising really given the small benefit anyway a second antiplatelet has in this setting @JACCJournals https://t.co/TWgcKnp6vL #CardioEd
El Ticagrelor versus Clopidogrel en pacientes post Infarto solo manejados con fibrinolisis, no produjo mejoras sustanciales en mortalidad cv: TREAT Trial https://t.co/C9JjKKpjpW
#ACC19 TREAT Trial https://t.co/ZEtBI413hU